Bioprinting in cancer treatment: improving models, accelerating drug development and overcoming research challenges

Published: 14-May-2025
Research & Development Pharma 5.0

As global cancer diagnoses increase — projected to reach 35 million new cases annually by 2040 — the need for more effective and economically sustainable oncology therapies has never been more urgent

You need to be a subscriber to read this article.
Click here to find out more.

Standard treatment pathways that rely on “trial-and-error” approaches or conventional population-based drug testing often yield suboptimal outcomes, prolonged patient suffering and staggering expenses.

Vidmantas Šakalys, CEO at Vital3D Technologies, reports. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Vital3D
See more

You may also like

Research & Development

ICR London uncovers potential of tazemetostat-DOT1L inhibitor combo in blood cancer treatment

Read more
Combining tazemetostat with a DOT1L inhibitor caused tumour shrinkage in a DLBCL animal model — as opposed to an almost tripling of size in those treated with tazemetostat alone

Trending Articles

  1. SynaptixBio selects H-ABC antisense oligonucleotide for clinical progression The company will assess the safety and efficacy of SB H-19642 for the treatment of Hypomyelination with Atrophy of the Basal Ganglia and Cerebellum (H-ABC)
  2. AstraZeneca to progress development of Quell Therapeutics' IBD Treg AstraZeneca will now perform IND-enabling studies on the cell therapy candidate, facilitating its clinical development
  3. Optimized degasser improves reliability of polymer analysis instruments Biotech Fluidics collaborates with Polymer Char to enhance viscosity data precision
  4. BioDuro and Silicogenix join forces to lower complex therapeutic development barriers The companies plan to facilitate the rapid and cost-effective testing and development of complex therapeutic molecules
  5. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows companies to assess their process configurations in unprecedented detail and explore the decision space without time- and labour-intensive experiments

Upcoming event

BIO International Convention

3-6 June, 2024 | Convention | Boston, US See all

You may also like

Research & Development

ICR London uncovers potential of tazemetostat-DOT1L inhibitor combo in blood cancer treatment

Combining tazemetostat with a DOT1L inhibitor caused tumour shrinkage in a DLBCL animal model — as opposed to an almost tripling of size in those treated with tazemetostat alone
Regulatory

AlzeCure's topical pain gel gets into the FDA good books following Phase II trial

The FDA has stated its positive opinion on a preIND application submitted ahead of AlzeCure's Orphan Drug Designation application
You need to be a subscriber to read this article.
Click here to find out more.
Digital

Designing tomorrow’s medicines with generative AI and quantum computing

As the scale of biological complexity increases, so too must the tools we use to compute it. Pushing beyond the capabilities of classical technology into the realms of generative AI and quantum science, researchers are turning to more advanced techniques to keep up
Research & Development

Chiesi Group licenses two of Key2Brain's BBB-crossing therapeutic candidates

Chiesi will now globally develop and commercialise Key2Brain's therapeutic candidates for ultra-rare liposomal conditions, alpha-mannosidosis and Krabbe disease
Manufacturing

Optimized degasser improves reliability of polymer analysis instruments

Biotech Fluidics collaborates with Polymer Char to enhance viscosity data precision
Research & Development

BioDuro and Silicogenix join forces to lower complex therapeutic development barriers

The companies plan to facilitate the rapid and cost-effective testing and development of complex therapeutic molecules
Research & Development

SynaptixBio selects H-ABC antisense oligonucleotide for clinical progression

The company will assess the safety and efficacy of SB H-19642 for the treatment of Hypomyelination with Atrophy of the Basal Ganglia and Cerebellum (H-ABC)
Subscribe now